@nytimes: Making ‘Every Patient Counts’ a Business Imperative

An interesting article by New York Times’ author Katie Thomas about the orphan drug market: Making ‘Every Patient Counts’ a Business Imperative.

Provectus’ orphan drug status for both melanoma and HCC (liver cancer) present interesting valuation drivers for end-game discussions.